CCI-779 (Temsirolimus) Exhibits Increased Anti-Tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells With Acquired Resistance to Cisplatin or Cetuximab
Journal of Translational Medicine - United Kingdom
doi 10.1186/s12967-015-0456-6
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2015
Authors
Publisher
Springer Science and Business Media LLC